Efficacy and safety of nabumetone in 5,421 patients with osteoarthritis of the hip and/or knee joints. A subgroup evaluation of an outpatient study involving 18,047 patients.
Fedder
M
M
Scientific Information Department, Pharma Atmos/Beecham-Wülfing, Neuss, Federal Republic of Germany.
Stroehmann
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002074:Butanones / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006621:Hip Joint / Q000187:drug effects*; D006801:Humans; D007719:Knee Joint / Q000187:drug effects*; D008297:Male; D000077430:Nabumetone; D010003:Osteoarthritis / Q000188:drug therapy*; D012449:Safety
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D000077430:Nabumetone